EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer

Bingqi Dong, Yanlun Gu, Xiaojiao Sun, Xin Wang, Ying Zhou, Zhuona Rong, Jixin Zhang, Xuedong Shi, Zhuo Zhang, Xu He, Lin Chen, Qingqing Xiong und 2 weitere

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202400673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Bingqi Dong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing, 100034, China. Hauptthemen laut MEDLINE: Anoikis, Prostatic Neoplasms, Bone Neoplasms, Tubulin. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone metastases occur in more than 70% of advanced prostate cancer (PCa) patients, leading to a poor prognosis. Resistance to detachment‐induced apoptosis, also known as anoikis, plays a crucial role in the onset of tumor metastasis. Targeting anoikis resistance is of immense therapeutic significance in repression of metastatic spread. In this study, based on an anoikis‐related prognostic risk model of PCa, this study identifies TUBB3 as a key anoikis‐related prognostic gene that is highly expressed in bone metastatic PCa. TUBB3 expression is increased in anoikis‐resistant PCa cells, and TUBB3 depletion significantly reverses anoikis resistance during extracellular matrix (ECM) detachment and inhibits anoikis‐resistance‐induced PCa cell invasion and migration as well as epithelial‐mesenchymal transition (EMT) process. TUBB3 knockdown significantly reduces αvβ3/FAK/Src axis activation, blocking its downstream oncogenic signaling. In addition, this work develops bone‐targeting lipid nanoparticles (BT‐LNP) based on bisphosphonate‐modified ionizable lipid for systemic delivery of siRNA targeting TUBB3 (siTUBB3). BT‐LNP‐delivered siTUBB3 therapy with localization in the bone microenvironment significantly attenuate PCa bone metastasis progression in vivo upon intravenous administration. These findings pinpoint that TUBB3, as a key regulator of anoikis resistance, is an effective therapeutic target in bone metastatic PCa and that BT‐LNP‐mediated systemic delivery of siTUBB3 can be developed as a novel therapeutic strategy for this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnoikisProstatic NeoplasmsBone NeoplasmsTubulinMaleHumansCell Line, TumorAnimalsMiceEpithelial-Mesenchymal TransitionNanoparticlesCell MovementRNA, Small InterferingMice, Nude

Stichwörter der Autor:innen

TUBB3bone microenvironmentintegrinlipid nanoparticleprostate cancer

Substanzen

TUBB3 protein, humanTubulinRNA, Small Interfering

Autor:innen und Institutionen

  • Department of General Surgery, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing, 100034, China.
  • Institute of Clinical Pharmacology, Peking University First Hospital, Xueyuan Road 38, Haidian District, Beijing, 100191, China.
  • Department of Pharmacy, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing, 100034, China.
  • School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, Beijing, 100191, China.
  • Department of Urology Surgery, Peking University Third Hospital, Xueyuan Road 38, Haidian District, Beijing, 100191, China.
  • Department of Pathology, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing, 100034, China.

ORCID-Profile: Yimin Cui

Förderung

  • National Natural Science Foundation of China
  • Beijing Municipal Natural Science Foundation

Zitieren

APA

Dong, B., Gu, Y., Sun, X., Wang, X., Zhou, Y., Rong, Z., Zhang, J., Shi, X., Zhang, Z., He, X., Chen, L., Xiong, Q., Pang, X., & Cui, Y. (2024). Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400673

Vancouver

Dong B, Gu Y, Sun X, Wang X, Zhou Y, Rong Z, et al. Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400673

BibTeX
@article{Dong2024,
  author = {Dong, Bingqi and Gu, Yanlun and Sun, Xiaojiao and Wang, Xin and Zhou, Ying and Rong, Zhuona and Zhang, Jixin and Shi, Xuedong and Zhang, Zhuo and He, Xu and Chen, Lin and Xiong, Qingqing and Pang, Xiaocong and Cui, Yimin},
  title = {Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202400673}
}
Kostenlos starten →